Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.67M Sell
110,872
-4,484
-4% -$117K 0.03% 164
2026
Q1
$3.24M Sell
115,356
-1,928
-2% -$51.3K 0.04% 136
2025
Q4
$2.92M Sell
117,284
-2,828
-2% -$71.3K 0.03% 149
2025
Q3
$3.06M Buy
120,112
+1,761
+1% +$43.5K 0.03% 139
2025
Q2
$2.87M Buy
118,351
+3,548
+3% +$82.7K 0.03% 140
2025
Q1
$2.91M Sell
114,803
-10,220
-8% -$267K 0.04% 126
2024
Q4
$3.32M Buy
125,023
+71,464
+133% +$1.94M 0.04% 113
2024
Q3
$1.5M Buy
53,559
+3,102
+6% +$90.5K 0.02% 200
2024
Q2
$1.4M Buy
50,457
+5,136
+11% +$141K 0.02% 178
2024
Q1
$1.26M Sell
45,321
-40,984
-47% -$1.14M 0.02% 166
2023
Q4
$2.86M Sell
86,305
-1,707
-2% -$51.6K 0.05% 78
2023
Q3
$3.23M Buy
88,012
+37,827
+75% +$1.34M 0.05% 78
2023
Q2
$2.05M Sell
50,185
-10,515
-17% -$409K 0.03% 106
2023
Q1
$3.11M Sell
60,700
-2,357
-4% -$102K 0.05% 91
2022
Q4
$2.76M Buy
63,057
+7,388
+13% +$354K 0.05% 94
2022
Q3
$2.92M Buy
55,669
+3,398
+7% +$165K 0.05% 79
2022
Q2
$2.71M Buy
+52,271
New +$2.66M 0.04% 82

Other funds holding PFE

Blue Trust Inc's PFE Position: Q2 2026 in Review

Blue Trust Inc reduced its Pfizer (PFE) stake by 3.9% in Q2 2026, selling an estimated $117K and leaving 110,872 shares worth $2.67M. The position accounts for 0.03% of the portfolio, ranked #164.

Blue Trust Inc first reported a position in PFE in Q2 2022 and has held it in 17 quarters since. The position peaked at $3.32M in Q4 2024. 1,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Blue Trust Inc held 110,872 shares of Pfizer worth $2.67M as of Q2 2026.
  • Blue Trust Inc sold 4,484 Pfizer shares in Q2 2026, an estimated $117K.
  • Pfizer made up 0.03% of Blue Trust Inc's portfolio in Q2 2026, its #164 holding.
  • Blue Trust Inc first reported a position in Pfizer in Q2 2022 and has held it in 17 quarters since.
  • Blue Trust Inc's Pfizer position peaked at $3.32M in Q4 2024.
  • 1,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.